Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta 1a - Synairgen

Drug Profile

Interferon beta 1a - Synairgen

Alternative Names: AZD 9412; inhaled interferon beta - Synairgen; SNG-001

Latest Information Update: 21 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Southampton
  • Developer AIDS Clinical Trials Group; Synairgen
  • Class Antiasthmatics; Antineoplastics; Antivirals; Interferons; Vascular disorder therapies
  • Mechanism of Action Immunostimulants; Interferon beta-1a replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections
  • Phase II Chronic obstructive pulmonary disease
  • No development reported Influenza virus infections
  • Discontinued Asthma

Most Recent Events

  • 17 Mar 2022 Synairgen halted enrolment in its phase III trials in COVID-2019 infections in Brazil, Canada, Philippines, South Africa, Mexico, Puerto Rico, Argentina and the US (Inhalation) (NCT04518410)
  • 21 Feb 2022 Efficacy and adverse events data from the phase III SPRINTER trial in COVID-2019 infections released by Synairgen
  • 11 Feb 2022 Synairgen completes the phase III SPRINTER trial in COVID-2019 infections (Inhalation) in the US, Argentina, Belgium, Brazil, Colombia, France, Germany, India, Israel, Italy, Mexico, Netherlands, Portugal, Romania, Serbia, Spain and the UK (NCT04732949) (EudraCT2020-004743-83)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top